-

SHL Telemedicine: Invitation to Conference Call Presenting Annual Results 2023

TEL AVIV, Israel & ZURICH & NEW YORK--(BUSINESS WIRE)--SHL Telemedicine Ltd. (SIX Swiss Exchange: SHLTN; NASDAQ: SHLT) ("SHL” or the “Company”), a leading provider and developer of advanced personal telemedicine solutions, today announced that it will publish its results for 2023 on Wednesday, April 17, 2024 at 7 am CET.

The conference call for investors, journalists, and analysts to discuss the annual results 2023 will be hosted by Yariv Alroy, Chairman, Erez Nachtomy, CEO, and Amir Hai, CFO, and has been scheduled for the same day as following:

Date: Wednesday, April 17, 2024
Time: 4 pm CET / 10 am ET / 5 pm Israel Time

The conference call can be accessed live via the below dial-in numbers:

From Europe

 

+41 (0) 58 310 50 00

From the UK

 

+44 (0) 207 107 06 13

From the USA

 

+1 (1) 631 570 56 13

From Israel

 

+972 3763 1173

Toll free:

 

1 80 921 44 27

Local:

 

+972 3763 1173

Other international numbers are available here.

After the presentation, there will be an open Q&A. The conference call is scheduled to last 40-60 minutes and will be held in English.

The press release and the presentations slides will be made available at the Company’s website www.shl-telemedicine.com at 7 am CET on April 17, 2024.

About SHL Telemedicine

SHL Telemedicine is engaged in developing and marketing personal telemedicine systems and the provision of medical call center services, with a focus on cardiovascular and related diseases, to end users and to the healthcare community. SHL Telemedicine offers its services and personal telemedicine devices to subscribers utilizing telephonic and Internet communication technology. SHL is listed on the SIX Swiss Exchange (SHLTN, ISIN: IL0010855885, Security No.: 1128957) and on the Nasdaq Stock Exchange (SHLT, ISIN: US78423T2006, CUSIP: 78423T200). For more information, please visit our website at www.shl-telemedicine.com.

Contacts

For any additional support, please contact Fabienne Farner, phone +41 43 244 81 42 or e-mail shl@irf-reputation.ch

SHL Telemedicine Ltd.

NASDAQ:SHLT

Release Versions

Contacts

For any additional support, please contact Fabienne Farner, phone +41 43 244 81 42 or e-mail shl@irf-reputation.ch

Social Media Profiles
More News From SHL Telemedicine Ltd.

SHL Telemedicine to Appoint David Arnon as CEO of SHL Telemedicine

TEL AVIV & ZURICH & NEW YORK--(BUSINESS WIRE)--SHL Telemedicine Ltd. (NASDAQ: SHLT, SIX: SHLTN;) ("SHL" or the "Company"), a leading provider and developer of advanced personal telemedicine solutions, has announced today that it has appointed Mr. David Arnon as CEO of the Company. He will join SHL Telemedicine and assume the role on August 6, 2024, succeeding Erez Nachtomy, who, as previously announced, will step down as CEO. Mr. Arnon has over 17 years of commercial and executive level managem...

SHL Telemedicine Confirms Discussions Regarding a Possible Investment in its Israeli Activity

TEL AVIV & ZURICH & NEW YORK--(BUSINESS WIRE)--SHL Telemedicine Ltd. (NASDAQ: SHLT, SIX: SHLTN;) ("SHL" or the "Company"), a leading provider and developer of advanced personal telemedicine solutions, has clarified today that it is in discussions with Discount Capital Ltd. the investment arm of Israel Discount Bank, regarding a possible investment relating to SHL’s Israeli activity. At this point, the parties have not yet taken any decision nor entered into any binding obligation with regard to...

SHL Telemedicine Expands Offering in Israel With Groundbreaking At-home Biomarker Blood Test

TEL AVIV, Israel & ZURICH & NEW YORK--(BUSINESS WIRE)--SHL Telemedicine Ltd. (NASDAQ: SHLT, SIX: SHLTN;) ("SHL" or the "Company"), a leading provider and developer of advanced personal telemedicine solutions, is proud to announce that it has expanded its offering in Israel to include the groundbreaking ability to perform at-home Biomarker blood tests. This diagnostic tool is designed to rapidly identify cardiac markers for detection of a heart attack, transforming emergency cardiac care with sp...
Back to Newsroom